Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy

• DOI: 10.1007/s12245-009-0125-8
• Publication Date: 2009-11-25T18:12:42Z
• Authors: Cezary Wójcik; Michelle L. Schymik; Eric G. Cure
• Keywords: Prothrombin complex concentrate; PROTHROMBIN COMPLEX; Angiology; Blood coagulation factors

The purpose of this study was to evaluate the effectiveness a new, fixed, yet individualized dosing regimen activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for warfarin reversal in setting life-threatening bleeding secondary care center. In report we present retrospective chart review 72 patients who received FEIBA and 69 fresh-frozen plasma (FFP) reverse effects bleeding. cohort, 500 units when initial INR <5 or 1,000 ≥5. administration resulted lower subsequent compared with FFP shorter time elapsed from drug an ≤1.4 FFP. No significant differences survival length hospital stay were observed. A higher dose induced bigger decrease than dose. We observed five adverse events (7%) that could potentially be related administration. presented results safe warfarin-induced coagulopathy, which appears faster more profound following Moreover, use PCC does not appear carry increased risk thrombotic rate reported several non-activated preparations.